HC Wainwright Reiterates “Buy” Rating for Pacira BioSciences (NASDAQ:PCRX)
Pacira BioSciences (NASDAQ:PCRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $57.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 90.89% from the company’s current price. […]
More Stories
What is Jimmy Dunne’s Net Worth? Biography and Complete Details
The Irish Footballer, Jimmy Dunne made an illustrative football career at a young age. The article gives you a glimpse...
Will There Be a Season 3 of Tehran?
The Emmy Award Winner, Tehran, has made headlines since its debut in 2020. With two seasons already streaming on Apple...
Soulgen AI Review: Is it the Best AI Image Generator?
Through this article, we will dive into one of the most exciting AI tools, Soulgen AI. We have also listed...
Is The Night Manager Returning After Eight Years With A New Season?
MCU’s Loki, Tom Hiddleston, is in talks for his role as The Night Manager. The article discusses the series, its...
Independent Advisor Alliance Buys 1,716 Shares of Vanguard Growth ETF (NYSEARCA:VUG)
Independent Advisor Alliance raised its holdings in Vanguard Growth ETF (NYSEARCA:VUG – Free Report) by 100.0% during the 4th quarter,...
Great Lakes Advisors LLC Has $4.29 Million Stake in Take-Two Interactive Software, Inc. (NASDAQ:TTWO)
Great Lakes Advisors LLC cut its stake in shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO – Free Report) by 2.9%...